• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

MIMETAS Launches Ready-to-Use 3D Colon Organoid Model for Drug Discovery

Leiden, September 8, 2024 – MIMETAS has introduced the OrganoReady® Colon Organoid, a first-of-its-kind, ready-to-use 3D colon model derived from adult stem cells. Designed to advance gastrointestinal toxicity screening, this high-throughput model offers seamless integration into laboratory workflows, streamlining drug development.

The OrganoReady Colon Organoid merges cutting-edge organoid technology with MIMETAS’ unique, membrane-free tubular cell culture platform, providing unrivaled apical and basolateral access. This feature enables precise testing for both oral and systemic drug exposure. Fully characterized with relevant biomarkers and transporters, the model is validated for multiparametric toxicity assessments, establishing it as a critical resource for drug developers.

“Our new colon organoid model provides a reliable, translatable platform for predicting toxicity, helping researchers address potential risks at every stage of development,” said Bas Trietsch, CTO at MIMETAS. “With the OrganoReady format, we deliver adult stem cell-derived organoid technology—pioneered by the Clevers group—directly to our customers. This eliminates the months or even years typically required for licensing, sourcing, and culturing, allowing researchers to simply open a blister pack and begin.”

Key Features:

  • 64 ready-to-use, perfusable colon tubules
  • Apical and basolateral access for comprehensive oral and intravenous drug testing
  • Full characterization with essential biomarkers and polarized transporter expression
  • Validated for toxicity screening, ensuring accurate, reliable results
  • Live human biology delivered directly to your lab
  • No licensing required

The OrganoReady Colon Organoid enables efficient compound de-risking, drug safety testing, and enhanced understanding of gastrointestinal toxicity mechanisms. Its physiological relevance offers researchers a robust tool for more accurate prediction of adverse drug events, enhancing decision-making in drug discovery.

Learn more about the OrganoReady Colon Organoid and how it can enhance your research:

Visit the Product Page Download Our App Note

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all